



Food and Drug Administration
9200 Corporate Boulevard
Rockville MD 20850

JUN - 6 2001

Mr. G. Baskaran
Managing Director
Brightway Holdings Sdn. Bhd.
Lot 1559, Jalan Istimewa,
Batu Belah, 42100 Klang,
Selangor Darul Ehsan
MALAYSIA

Re: K010856
Trade/Device Name: Sterile Brightway Brand
Powder-Free, Latex Examination Gloves, with Protein
Labeling Claim (50 micrograms or less) Tested For Use
with Chemotherapy Drugs (Carmustine, Fluorouracil,
Methotrexate)
Regulation Number: 880.6250
Regulatory Class: I
Product Code: LYY
Dated: March 5, 2001
Received: March 22, 2001

Dear Mr. Baskaran:

We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the Current Good Manufacturing Practice requirements, as set forth in the Quality System Regulation (QS) for Medical


Devices: General regulation (21 CFR Part 820) and that, through periodic QS inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory

action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.

This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4692. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its internet address "<http://www.fda.gov/cdrh/dsma/dsmamain.html>".

Sincerely yours,



Timothy A. Ulatowski
Director

Division of Dental, Infection Control
and General Hospital Devices
Office of Device Evaluation
Center for Devices and
Radiological Health

3.0 Indications for use

Applicant
S10(k) number
Device name

BRIGHTWAY HOLDINGS SDN. BHD.

K010856

BRIGHTWAY™ Brand Powder Free
Latex Examination Gloves

- Blue Color, Sterile
(containing 50 µgm or less of water
extractable protein per gram.)
(tested for use with Chemotherapy Drugs,
Carmustine, Fluorouracil, Methotrexate)


Indications for use:

BRIGHTWAY™ Brand Powder Free Latex Examination Glove, Blue Color, Sterile (containing 50 µgm or less of water extractable protein per gram) (tested for use with Chemotherapy Drugs Carmustine, Fluorouracil, Methotrexate) is a disposable Chemotherapy examination glove which is worn on the hand of healthcare and similar personnel to prevent contamination between patient and examiner and also to protect the examiner's hands from being affected by the chemicals used in therapy.

05/31/01

4

Doc. Ref. : BH/S10(k)/ChemLEG-S



(Division Sign-Off)
Division of Dental, Infection Control,
and General Hospital Devices
S10(k) Number K010856